SG11201809042SA - Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases - Google Patents

Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

Info

Publication number
SG11201809042SA
SG11201809042SA SG11201809042SA SG11201809042SA SG11201809042SA SG 11201809042S A SG11201809042S A SG 11201809042SA SG 11201809042S A SG11201809042S A SG 11201809042SA SG 11201809042S A SG11201809042S A SG 11201809042SA SG 11201809042S A SG11201809042S A SG 11201809042SA
Authority
SG
Singapore
Prior art keywords
salt
respiratory system
system diseases
treating respiratory
preparing drugs
Prior art date
Application number
SG11201809042SA
Inventor
Hongmei Gu
Shanchun Wang
Xiquan Zhang
Lei Huang
Hongjiang Xu
Wei Song
Ping Dong
Zhongying Sun
Ying Zhang
Deyang Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11201809042SA publication Critical patent/SG11201809042SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5 The present invention belongs to the field of medicine, relates to an preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
SG11201809042SA 2016-04-15 2017-04-14 Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases SG11201809042SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610237175 2016-04-15
PCT/CN2017/080583 WO2017177966A1 (en) 2016-04-15 2017-04-14 Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases

Publications (1)

Publication Number Publication Date
SG11201809042SA true SG11201809042SA (en) 2018-11-29

Family

ID=60042326

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809042SA SG11201809042SA (en) 2016-04-15 2017-04-14 Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
SG10202010192YA SG10202010192YA (en) 2016-04-15 2017-04-14 Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202010192YA SG10202010192YA (en) 2016-04-15 2017-04-14 Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

Country Status (12)

Country Link
US (2) US20190117568A1 (en)
EP (1) EP3443954A4 (en)
JP (2) JP7166929B2 (en)
KR (1) KR102410183B1 (en)
CN (2) CN111920785B (en)
AU (1) AU2017251548B2 (en)
BR (1) BR112018071208A2 (en)
EA (1) EA201892350A1 (en)
MX (1) MX2018012461A (en)
PH (1) PH12018502195A1 (en)
SG (2) SG11201809042SA (en)
WO (1) WO2017177966A1 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
AU2003252493A1 (en) 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
JP2009513529A (en) 2003-07-11 2009-04-02 グラクソ グループ リミテッド Pharmaceutical formulations containing magnesium stearate
CN101023953B (en) * 2006-07-24 2010-05-12 南开大学 Composition for treating bronchia asthma
CN101190232B (en) * 2006-11-30 2011-08-17 江苏正大天晴药业股份有限公司 Magnesium isoglycyrrhizinate freeze dried powder injection for injection and preparation method thereof
JP2008222682A (en) * 2007-03-15 2008-09-25 Kumamoto Univ Medicine for treatment of fibrotic lung disease, agent for suppressing airway mucous secretion cell hyperplasia and medicine for treatment of airway embolism
CN101396368B (en) * 2007-09-29 2010-12-01 江苏正大天晴药业股份有限公司 Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis
CN101669962A (en) * 2009-09-18 2010-03-17 杭州市第六人民医院 Composite glycyrrhizic acid amino acid injection, and preparation method as well as applications thereof
WO2012026928A1 (en) * 2010-08-25 2012-03-01 Diacarta Llc Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN103156930A (en) * 2011-12-19 2013-06-19 张亚军 Respiratory tract dosing preparation containing extract of paeonia lactiflora and licorice
TWI586378B (en) 2012-03-13 2017-06-11 瑞斯比維特有限公司 Novel pharmaceutical formulations
CN102920936A (en) * 2012-09-17 2013-02-13 陈泉生 Salt absorber for treating respiratory diseases and preparation method thereof
CN104042573A (en) * 2014-06-03 2014-09-17 青岛市市立医院 Magnesium isoglycyrrhetate freeze-dried powder injection and preparation method thereof
CN106237297A (en) * 2016-08-30 2016-12-21 吉林紫鑫药业股份有限公司 A kind of pharmaceutical composition for treating chronic bronchitis

Also Published As

Publication number Publication date
MX2018012461A (en) 2019-09-18
US20200368158A1 (en) 2020-11-26
KR20180132143A (en) 2018-12-11
US11534398B2 (en) 2022-12-27
EA201892350A1 (en) 2019-06-28
AU2017251548A1 (en) 2018-11-15
JP7166929B2 (en) 2022-11-08
PH12018502195A1 (en) 2019-09-23
CN109069442A (en) 2018-12-21
CN111920785A (en) 2020-11-13
CN109069442B (en) 2020-09-04
JP7309791B2 (en) 2023-07-18
JP2021176903A (en) 2021-11-11
CN111920785B (en) 2022-05-20
KR102410183B1 (en) 2022-06-17
WO2017177966A1 (en) 2017-10-19
JP2019511556A (en) 2019-04-25
EP3443954A1 (en) 2019-02-20
AU2017251548B2 (en) 2022-02-17
SG10202010192YA (en) 2020-11-27
BR112018071208A2 (en) 2019-02-12
EP3443954A4 (en) 2019-11-20
US20190117568A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
CY1121698T1 (en) LIQUID INHALATION PREPARATION CONTAINING RPL554
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
IN2015DN03219A (en)
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2021004558A (en) Proton-binding polymers for oral administration.
MX2018012538A (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2015012315A (en) Use of levocetirizine and montelukast in the treatment of traumatic injury.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
IN2014DN09240A (en)
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
SG11201809042SA (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite
WO2018084817A3 (en) A new form of active agent
MX2018004295A (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof.
UA98397U (en) A method of treating pislyapromenevih pulmonary lesions in lung cancer patients
TH167851B (en) (S) - Perlindole And its pharmaceutical acceptable salt for Use in medicine